Targeted Medical Pharma Combats the Epidemic of Pain with Release of THERALEVE™

Los Angeles, — Targeted Medical Pharma, Inc. (OTCQB: TRGM) in conjunction with Amino Nutritionals LLC, today announced the consumer release of THERALEVE™ (www.theralevehealth.com) a patented amino acid based formula designed by pain management physicians to help the 100 million chronic pain sufferers in the United States, fight pain and inflammation without the dangerous side effects commonly associated with NSAIDs and opioids. “Common pain medications do not address the nutritional needs of the nervous system and only target symptoms of pain. THERALEVE provides a specific blend Continue reading →

TARGETED MEDICAL PHARMA BREAKS GROUND IN THE CONSUMER GOODS MARKET

Targeted Medical Pharma, Inc. (OTCQB: TRGM), announced the establishment of a new subsidiary, Amino Nutritionals LLC, that will specialize in the development and marketing of THERALEVE™, a proprietary consumer product for chronic pain sufferers to be sold in the United States and abroad. The Company is pleased to announce the hiring of Joshua Levine as the Vice President of Direct Consumer Sales. Mr. Levine will spearhead the direct marketing efforts for Amino Nutritionals, and will be responsible for building the infrastructure required for market development Continue reading →

Research Identifies a Potential New Path to Developing a Treatment for Chronic Pain

Los Angeles, September 8, 2015 – Targeted Medical Pharma to present new chronic pain research that reveals significant nervous system abnormalities among patients suffering from Fibromyalgia, at the 2015 PainWeek national conference in Las Vegas, Nevada. The study looked at 329 Fibromyalgia patients and 58 control patients all of whom wore Holter monitors for a 24 hour period to measure nervous system activity. The results of this study showed that patients with Fibromyalgia experience a significant decrease in both nighttime parasympathetic nervous system (PNS) activity and daytime sympathetic Continue reading →

New Research Finds a Link Between Obesity and Nutritional Deficiencies

Los Angeles, CA, April 27, 2015 — Obesity has reached epidemic proportions affecting nearly 78 million adults in the United States and has been linked with an increased risk of diabetes, heart disease, and cancer. Recent studies have suggested that obese patients have specific amino acid deficiencies that can contribute to obesity. The latest research report entitled “Nutritional Deficiencies Associated with Obesity,” published online in the Journal of Obesity and Weight Loss Therapy, highlights the specific amino acid and nutrient deficiencies that are commonly associated Continue reading →

Targeted Medical Pharma Announces New Partnership for Exclusive Distribution in Japan

Los Angeles, February 19,  2015 – Targeted Medical Pharma (OTCQB: TRGM), today announced the completion of an exclusive product distribution agreement with J-Network Inc., a  California-based company that specializes in distributing cosmetic and healthcare goods exclusively to Japan. The Agreement grants J-Network an exclusive one-year renewable license for the marketing and sales of the Company’s proprietary product, designed to improve sleep and immune function, in Japan. Under the terms of the Agreement, Targeted Medical Pharma will develop new products specific for import into the Japanese Continue reading →

Targeted Medical Pharma Releases Promising Trial Results for the Treatment of Posttraumatic Stress Disorder

Study Shows Medical Foods Sentra AM and Sentra PM Effective at Reducing Symptoms of PTSD in Veterans Los Angeles, CA, October  13, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) a drug discovery and development company, today announced the results of a clinical trial studying the amino acid based medical foods, Sentra AM and Sentra PM in Veterans suffering from symptoms associated with Posttraumatic Stress Disorder (PTSD). In this 30 day open label pilot study (n=21), published in the Journal of Central Nervous System Disease, Continue reading →

Clinical Trial Results Confirm Amino Acid Based Medical Food Theramine® More Effective at Improving Chronic Back Pain than NSAID Pain Medications

Los Angeles, CA, September  23, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) a drug discovery and development company, announced the results of a second, double-blind clinical trial which confirmed that Theramine was shown not only to be more effective than ibuprofen in reducing low back pain, but also demonstrated a significant reduction in measures of inflammation. In this 28 day, multi-center trial, subjects taking Theramine as either a standalone medication or in conjunction with a low dose ibuprofen, demonstrated a significant reduction in both Continue reading →

Targeted Medical Pharma to Present at Sachs Associated 14th Annual Biotech in Europe Forum for Global Partnering and Investment

Los Angeles, September 16, 2014 — Targeted Medical Pharma (OTCQB:TRGM), today announced that William Shell, M.D., Chairman, CSO and CEO  is scheduled to present the latest company information regarding the advances in therapeutic nutrition and medical foods technology, at the 14th Annual Biotech in Europe Forum at the Congress Center in Basel, Switzerland. The presentation is scheduled for September 30th, 2014 at 11:45 am in the Lima Room. Dr. Shell will also be a panelist in the discussion regarding advancements in Neuroscience at 3:30 pm. Additional information Continue reading →

Targeted Medical Pharma Reports Second Quarter 2014 Financial Results

Los Angeles, CA, August 14, 2014 – Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced financial results for its second quarter ended June 30, 2014.  The Company posted increased revenues, gross profit and an increase in net income before interest, taxes, depreciation and amortization, and stock based compensation (Adjusted EBITDA*) on a quarter-over-quarter basis. Financial Overview Quarter-over-Quarter Comparison: Financial results for the three months ended June 30, 2014 compared to the three months ended June 30, 2013 Total revenue of $2.2 million, a 16% improvement Continue reading →

Targeted Medical Pharma to Sponsor Clinical Trial Conducted by U.S. Army and Henry M. Jackson Foundation

Study to Examine the Use of Theramine for the Treatment of Acute or Sub-Acute Lower Back Pain due to Injury Los Angeles, CA, July 28, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced the completion of an agreement to sponsor an investigator-initiated study with the United States Army and The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. (HJF). The study, which is slated to start enrolling patients in Q2 of 2014, will involve the Company’s medical food Theramine. The Continue reading →